🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT03720704
Active, not recruiting Observational

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

NCT03720704 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2018-12-18
Last updated
2026-04-14

Condition(s) studied

Peripheral Vascular Diseases

Investigational drug(s) / intervention(s)

GORE VIABAHN VBX Balloon Expandable Endoprosthesis

GORE VIABAHN VBX Balloon Expandable Endoprosthesis: GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.

Study summary

The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require interventional treatment

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Signed informed consent form * Endovascular indication for treatment based on treating physician's best medical judgment. * Intend for no other stents to be placed in the same peripheral vessel(s) targeted for VBX Stent Graft placement. * Willingness of the patient to adhere to standard of care follow-up requirements. Exclusion Criteria: * Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. * Participation in concurrent research study or registry which may confound registry results, unless approved by Gore. * Pregnant or breast-feeding female at time of informed consent signature. * Life expectancy \< 12 months due to comorbidities. * Use of the VBX Stent Graft is for the treatment of de novo iliac occlusive disease. * Use of the VBX Stent Graft is for the treatment of aortic coarctations. * Use of the VBX Stent Graft in the coronary, pulmonary, carotid, vertebral, isolated infrarenal aortic, or vena cava vessels.

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Hôpital Marie Lannelongue Paris France
University Hospital Heidelberg Heidelberg Germany
St. Franziskus Hospital Münster Germany
Azienda Ospedaliera Policlinico Sant'Orsola Malpighi Bologna Italy
Fondazione Poliambulanza Brescia Italy
Azienda Ospedaliero-Universitaria di Padova Padova Italy
Ospedale di Circolo e Fondazione Macchi Varese Italy
University Medical Center Groningen Groningen Netherlands
Erasmus Medical Center Rotterdam Netherlands
Hospital Universitario Central de Asturias (HUCA) Oviedo Spain
University Hospital of Santiago de Compostela Santiago de Compostela Spain

More W.L.Gore & Associates trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03720704 on ClinicalTrials.gov ↗ ← All trials in Spain